KemPharm (KMPH) Tops Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
KemPharm, Inc. Reports First Quarter 2016 Results
May 12, 2016 4:06 PM EDT
Recent Clinical Development & Regulatory Highlights:
Introduced Apadaz as the proprietary name for KP201/APAPFDA Advisory Committees voted 16 to 4 in support of Apadaz approval; voted 18 to 2 against inclusion of abuse deterrent labelingGranted Fast Track designation for, and received clearance from FDA to initiate human clinical trials, of KP511, KemPharms prodrug of hydromorphone
Recent Corporate and Financial Highlights:
... More
